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Introduction
Fabry disease (FD) is a rare, X-linked lysosomal storage disorder caused by deficiency in the enzyme α-galactosidase A. This leads to slowly progressive sphingolipid accumulation affecting multiple organs including the heart, kidneys and brain(1). Males are affected earlier than females (average age of cardiac symptoms 32 vs 40 years) (2, 3) . Cardiac manifestations include left ventricular hypertrophy (LVH), arrhythmias, chronic inflammation(4), myocardial fibrosis and functional impairment (5) . Cardiovascular death is the leading cause of death in both males and females (6, 7) , with LVH and myocardial fibrosis being amongst the suggested risk factors for ventricular arrhythmia and sudden cardiac death (8) . Treatment options in FD include enzyme replacement therapy (ERT), which has been the mainstay therapy, and more recently oral chaperone therapy, which is available for amenable mutations (9) . Sphingolipid storage over time appears to trigger myocardial processes including LVH and irreversible myocardial fibrosis. Although specific phases of cardiac involvement are ill defined, early initiation of treatment appears desirable to avoid irreversible and progressive phenotype alterations (10) .
The cardiac phenotype in FD has been increasingly understood by cardiovascular magnetic resonance (CMR) over the past 15 years. Early data showed the presence of late gadolinium enhancement (LGE) in approximately 50% of patients, initially in the basal inferolateral wall in FD (11) , sometimes occurring before LVH in females (12) or in some mutations in males (13) . Recent advances in CMR allow quantitative assessment of the myocardium using fundamental magnetic tissue relaxation constants, for example T1, which are displayed as parametric color maps.
Sphingolipid-or at least the specific configuration in lamellar bodies appears to be the cause of the low T1 and occurs in 85% of FD with LVH and 40-50% of FD without LVH (14) (15) (16) . Low T1 has also been observed in FD with right ventricle hypertrophy (17) . The T1 signal however reflects the whole myocardium: whilst fat lowers T1, pseudonormalisation has been previously hypothesised in advanced disease -either with triggered hypertrophy diluting the storage signal or with fibrosis (high T1) normalizing it (14) . There is well-documented data on differences in Fabry cardiomyopathy between male and female FD by transthoracic echocardiography and CMR with LGE (12) . We sought to refine further our understanding of myocardial disease development using a multiparametric CMR approach in a large cohort of adults and children, male and female FD.
Methods

Study population
A prospective observational study in 182 FD patients. Ethical approval was obtained from the local research ethics committee. Participants were recruited from Fabry clinics at Royal Free Hospital and National Hospital for Neurology and Neurosurgery in London. Inclusion criteria included gene-positive FD; both males and females; children (<18 years old) and adults (≥18 years).
All participants underwent CMR and 12-lead electrocardiogram (ECG). Blood samples were performed on adults just before the scan and analysed for estimated glomerular filtration rate (eGFR), high-sensitivity troponin T (Roche Diagnostic; normal range 0-14ng/L) and N-terminal pro-brain natriuretic peptide (NT-proBNP) analysis (Roche Diagnostics; normal range according to age and gender)(18).
CMR imaging
CMR was performed (1.5 Tesla Avanto, Siemens Healthcare, Erlangen, Germany) using a standard clinical protocol. LGE images were acquired in the standard long axis and short axis stack using either fast long angle shot (FLASH) sequence or a respiratory motion-corrected free-breathing single short steady state free precession (SSFP), averaged sequence (MOCO-LGE), both with phase sensitive inversion recovery. Before contrast administration (0.1 mmol/kg body weight, Gadoterate meglumine, Dotarem, Guerbet S.A., France), T1 mapping was performed using a shortened modified Look-Locker inversion recovery (ShMOLLI) sequence on basal and mid left ventricular short axis slices. The resulting pixel by-pixel T1 color maps were displayed using a customized 12-bit lookup table, where normal myocardium was green, increasing T1 was red, and decreasing T1 was blue. Post-contrast T1 mapping was performed 15 minutes after gadolinium administration for assessment of extracellular volume fraction (ECV) quantification. Contrast was not administered in participants age <18 years, eGFR <30ml/min/1.73m 2 or if the patient declined.
CMR analysis
All imaging analysis was performed using CVI42 software (Circle Cardiovascular Imaging Inc., Calgary, Canada). A region of interest for native T1 and ECV was manually drawn in the septum, taking care to avoid the blood-myocardial boundary with a 20% offset. LVH was defined as maximum wall thickness (MWT) >12mm in adults or increased indexed left ventricular mass (LVMi) on CMR according to age and gender matched normal reference ranges in adults and children (19, 20) . Normal T1 reference ranges (mean ± 2 standard deviations) were defined using 73 adult healthy volunteers (mean age 49±14 years): normal range total population 958±56ms, lower limit 902ms; male subgroup normal range 947±46ms, lower limit 901ms and female subgroup normal range 972±56ms, lower limit 916ms (21) .
ECG analysis
The ECGs were independently analysed by 2 experienced observers (S.N, S.B).
Recorded ECG variables included: heart rate, rhythm, PR interval duration (normal 120-200ms) and QRS complex duration (normal <120ms). The presence of complete left or right bundle branch block, T wave inversion in at least two contiguous leads, multifocal ventricular ectopics and Sokolow-Lyon voltage criteria for LVH (SV1 + RV5 or RV6 >35mm) were also recorded.
Statistical analysis
Statistical analyses were performed using SPSS 24 (IBM, Armonk, NY). Continuous variables were expressed as mean ± standard deviation or median ± interquartile range according to normality using Shapiro-Wilk test. Troponin and NT-proBNP values were natural log transformed for bivariate testing. Categorical variables were expressed as percentages. Group testing was independent-sample t-test, Mann-Whitney U test, Chi-squared test or Fisher exact test according to normality, categorical or continuous data. Correlations between parameters were analysed using Pearson (r) or Spearman's rho (r s ). Difference in regression slopes was determined using analysis of covariance. The relationship between LGE and clinically relevant variable was evaluated using logistic regression model to identify the independent associations of the dependent variables. A p-value of <0.05 was considered statistically significant.
Results
There were 182 participants: 167 adults and 15 children. Baseline characteristics are shown in Table 1 . Mean age of the FD cohort was 42±17 years, male gender 37% (68/182). Mean eGFR was 82±17 ml/min/1.73m 2 . 11 patients had eGFR <60 ml/min/1.73m 2 . 37 patients did not receive contrast at CMR. This is mainly due to patient preference, 3 patients had poor eGFR excluding contrast administration. 30% (55/182) had the cardiac variant (22) . Of this group, 91% (50/55) had N215S mutation, 5% (3/55) R301Q mutation and 4% (2/55) I91T mutation. 51% (92/182) of patients were on ERT with a median ERT duration of 7±6.4 years.
In the adult cohort (n=167), mean age was 45±15 years (range 18-81 years). 28% (47/167) were of cardiac variant and 37% male (62/167), ERT in 54% (91/167). In children (n=15): median age was 11±5 years (range 6-16 years), 53% (8/15) were of cardiac variant (all N215S mutation) and 40% male (6/15). Only one child was on ERT (for uncontrolled acroparesthesia).
Age related trends of T1
Children: All children were LVH-negative with normal function (mean LVEF 68±6%, LVMi 54±12g/m 2 , MWT 7±1mm). The children did not receive gadolinium so precluding assessment of LGE and ECV. No child had a low T1 (mean native T1 971±31ms), but T1 fell linearly with increasing age (figure 1a). Extrapolating the curve to adulthood, the curve cuts the lower limit of normal at the age of 18 (r -0.78, p<0.001; figure 1a).
Adults: Mean LVEF in FD adults was 73±7%. 3 adults had mildly impaired LV function with LVEF between 49-54%. Of the male FD with LVH, 98% (44/45) had low T1 (Figure 2a ). The one patient with normal T1 had extensive LGE involving multiple segments including the septum. Of the female FD with LVH, 90% (28/31) had low T1 and those with normal T1 all had apical LVH.
With increasing age, T1 falls, but the trend is less strong than in children (r -0.41, p<0.001) ( Figure 1b ). Over the whole cohort, this was more marked in males (males -1.9ms/year, r -0.51 males, p<0.001; females -1.4ms/year, r -0.47 females, p<0.001, figure 1b). When T1 is compared with LVH, however, the relationship was sex specific. Before LVH is present, with increasing LVMi, T1 falls in both sexes but more markedly in males (r -0.54, p<0.001 in male; r -0.276, p=0.01 in female; figure   2 ). After overt LVH is present, a major sex dimorphism is found. In males, the LVH is more extreme, and the correlation reverses (r +0.631, p<0.001), although almost all are below the lower limit of normal (pseudonormalization). In females, once LVH is present, T1 is not related to the degree of LVH (r -0.239, p>0.05).
Age and sex related trends for all parameters
LVH: LVH was more prevalent in males (66% [45/68] compared to 27% [31/114] in females, p<0.001). In both sexes, the prevalence of LVH increased with age ( Figure   3a male, 3b female). There were two main differences between males and females firstly phenotype development of LVH was later in women (effectively complete penetrance by 40-49 years in males, and 60-69 years in females). Secondly, when present, the LVH was more severe in men (figure 2) -with LVMi in males ranging up to 2.6x average LVMi (based on normal reference ranges) and 1.7x average LVMi for females. The highest MWT in males was 30mm and in females was 26mm.
LGE:
LGE prevalence was higher in males than in females (59% [32/54] vs 37% 
ERT:
In general, patients on ERT had higher MWT (14±5 vs 10±3mm), LVMi (98±42 vs 69±26 g/m 2 ) and lower septal T1 value (876±43 vs 916±60 ms), all p<0.001. ERT use was increasingly common with age in both males and females, but the age group of ERT initiation was similar between sexes (10-19 years). In males, 78% (36/46) with LVH were on ERT and 74% (23/31) in females, both p<0.005.
There is no significant correlation between T1 value and ERT duration in the total cohort (r s 0.004 p=NS). No strong correlation was found between ERT duration and between T1 values in males and females (r s 0.290 male and -0.029 female, both p=NS). There is a downward trend between age of ERT initiation and T1 values (r s -0.30 male and -0.44 female, both p<0.05). The trend of LVMi and T1 between males and females were similar in patients on ERT compared to patients who are ERT-naïve ( Figure 5 ).
Discussion
We sought insight into myocardial phenotype development in FD by looking at a large cohort of patients (including children) and measuring multiple parameters: LVH, scar (LGE), blood biomarkers and importantly T1 -a quantitative myocardial signal that is reduced by sphingolipid storage. The data shows that no child had overt T1 lowering of storage, but that T1 falls through childhood suggesting progressive subclinical accumulation. In children and adults, the fall in T1 with age is steeper with males compared to females, suggesting storage is faster in males. Males had earlier ECG abnormalities, blood biomarker increase, LVH and slightly earlier LGE; with
LGE in LVH negative subjects only occurring in females. Once LVH occurs, male hypertrophy is far more extreme than females (even when indexed), and the relationship of LVH to T1 changes: in females T1 falls until LVH is present when it is broadly flat, but in males, after LVH is present, T1 is higher (more normal) with increased LVH. What does the apparent T1 rise in males mean? Storage cannot be the cause (or T1 would be falling). T1 is a composite signal from myocardial interstitium (fibrosis, edema -high T1), capillary blood (high T1), myocyte sarcomeric protein (presumed normal T1) and sphingolipid storage (low T1). With this framework, there are multiple possible explanations: diffuse fibrosis, edema or capillary vasodilatation pseudo-normalizing T1 appears unlikely as all these increase ECV, which was normal in this study; focal fibrosis would explain the one patient with extensive LGE and normal T1, but not the others; removal of storage by ERT -a plausible scenario, but firstly, this would likely cause at least some LV mass regression and secondly, given most males and females with LVH are on ERT, enzyme would need to be more efficient in males which appears unlikely. We believe the answer is that in males, storage is triggering sarcomeric protein expression -myocyte hypertrophy (23, 24) , usual LVH rather than storage LVH, and that this is diluting the T1 lowering of sphingolipid. This would mean that there are two types of sex dimorphism in FD: that affecting all tissues (related to the second functional copy of the alpha galactosidase gene in females); and a cardiac specific sex dimorphism related to the male myocyte response to insult, here storage. Sex dimorphism in myocyte hypertrophy is familiar from other cardiac diseases: the hypertrophy in aortic stenosis is far more marked in males than females (25) , and probably observed in other conditions -for example, hypertrophic cardiomyopathy, a non-sex linked disease that has a male predominance in most large studies (26) . Whether FD, AS and HCM hypertrophy of sex dimorphism derive from common mechanisms is unknown at this time. Differential expression of androgen and estrogen receptors and differences in the renin-angiotensin system, nitric oxide activity, and norepinephrine release may contribute to sex differences observed in LV remodeling (25, 27, 28) .
Based on these findings, our prior work on LVH-negative patients and on LGE including inflammation imaging(4), we hypothesize a model of myocardial phenotype evolution in Fabry disease consisting of an accumulation phase, a hypertrophy and inflammation phase, and a fibrosis and impairment (late) phase ( Figure 6 ). This later phase is underrepresented in our study, partly as these patients have devices or have a significant mortality rate.
Accumulation phase:
Silent storage phase -starting in childhood, sub-clinical. Myocardial T1 is normal but falling. Minor architectural changes in cardiac morphology may be present.
Overt storage phase -T1 is now low and progressing faster in males than females, associated with LV mass within normal limits and associated with ECG changes.
Myocyte hypertrophy and inflammation phase:
LGE and inflammation mainly in the basal inferolateral wall, associated with persistent chronic troponin elevation but no thinning. This may occur before LVH in females (and Taiwan IVS4 subjects) (13) .
LVH, demonstrating sex dimorphism: in females, consisting of likely balanced sphingolipid and myocyte hypertrophy in proportion; in males, consisting mainly of increasing myocyte contractile protein -true hypertrophy with the T1 fall becoming less prominent.
Fibrosis and impairment phase:
Persistent LVH and troponin elevation but now fibrosis (myocyte death) and thinning occur.
LGE can be found extensively outside the basal inferolateral wall together with NT-proBNP elevation, LV impairment and clinical heart failure.
Our group and others have shown that ECV is normal in Fabry disease. (15, 29) The difference in ECV between male and female is most likely explained by normal sex differences where ECV in FD (15) and in healthy controls is known to be higher in female than in male (15, 29, 30) with more change over time observed in males which could be related to higher prevalence of myocyte hypertrophy or myocardial fibrosis in males with increasing age (Figure 3) . We have previously shown that LGE in established FD is chronic inflammation strongly correlating with troponin levels(4), supporting findings by PET/MR study (31) and endomyocardial biopsy (32) . Here again, troponin was independently and strongly related to LGE, although we do not report T2 values in this paper.
Limitations of this study include no histological validation of the presence of storage
with low native T1 in this study. The shape (linear/non-linear) of the relationship of sphingolipid to storage is unknown. There were no controls for the cohort of children although we note that T1 mapping in healthy controls in children might be comparative to healthy controls value in adults with no age effect in T1 values in the pediatric group (30, 33) . In addition, this is also a single center study with single timepoint data so our findings are hypothesis generating only based on our experiences and knowledge collaborated from all of our published works. We acknowledge that further longitudinal studies are needed and are currently being undertaken.
Conclusion
Sphingolipid accumulation potentially starts in childhood, proceeds more markedly in males than females before triggering a sex-independent scar or inflammation response but a sexually dimorphic myocyte hypertrophic response in males. Multi-timepoint longterm follow-up studies are needed to explore this further.
CLINICAL PERSPECTIVES
Competency in Medical Knowledge:
Fabry disease is an X-linked storage disease and the leading cause of death is cardiomyopathy. Storage can now be detected by measuring T1. This study proposes phases of cardiac involvement with storage apparently starting in childhood, accumulating faster in males before triggering new processes: regional scar and inflammation (male and female), and apparent myocyte hypertrophy (more in males) before advanced disease (extensive scar and LV impairment).
Translational Outlook:
Fabry disease is currently treated with enzyme replacement therapy. Treating cardiac disease will be key to improving outcomes. This paper suggests cardiac disease starts early, in childhood and has different stages and activated pathways. Additional The slope regression between male and female is statistically significant (p<0.001). LGE=late gadolinium enhancement, LVH=left ventricular hypertrophy, LVMi=indexed left ventricular mass, NS=not significant 
